Research Article: Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from Community Hospitals
Introduction:
Acute coronary syndrome (ACS), consisting of ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA), is commonly associated with a high risk of subsequent cardiovascular events and mortality beyond the first year after the event. , Post-event lipid-lowering therapy (LLT), including statins, ezetimibe, and proprotein convertase subtilisin/kexin type inhibitor monoclonal antibodies (PCSKi mAbs), is a vital part of secondary prevention treatment. – A…
Read more